Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.